Literature DB >> 15288345

Validation of an ocular microdialysis technique in rabbits with permanently implanted vitreous probes: systemic and intravitreal pharmacokinetics of fluorescein.

Banmeet S Anand1, Harisha Atluri, Ashim K Mitra.   

Abstract

The purpose of this work is to validate a novel ocular microdialysis sampling technique in rabbits with permanently implanted vitreous probes. This objective is achieved by studying the vitreous pharmacokinetics of fluorescein following systemic and intravitreal administration. The rabbits were divided into two groups (groups I and II) based on whether or not they were allowed a recovery period following surgical implantation of probes. The integrity of the blood-retinal barrier was determined by the vitreal protein concentrations and the fluorescein permeability index. Vitreal protein concentrations returned to baseline 48 h after probe implantation and therefore experiments were conducted 72 h post-implantation of probes in rabbits where recovery period was allowed. The permeability indices for fluorescein after systemic administration in group I (without recovery period) and group II (with recovery period) indicated that the integrity of the blood-retinal barrier was maintained and were found out to be 0.55 +/- 0.27 and 0.71 +/- 0.38%, respectively, for the vitreous chamber. Following microdialysis probe implantation in the group II rabbits, the blood-retinal barrier integrity was not compromised. A novel microdialysis technique in rabbits with permanently implanted probes for studying the pharmacokinetics of posterior segment has been developed and characterized.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15288345     DOI: 10.1016/j.ijpharm.2004.05.028

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  7 in total

1.  Prediction of the vitreal half-life of small molecular drug-like compounds.

Authors:  Heidi Kidron; Eva M Del Amo; Kati-Sisko Vellonen; Arto Urtti
Journal:  Pharm Res       Date:  2012-07-10       Impact factor: 4.200

2.  Retina-choroid-sclera permeability for ophthalmic drugs in the vitreous to blood direction: quantitative assessment.

Authors:  Nahid Haghjou; Mohammad J Abdekhodaie; Yu-Ling Cheng
Journal:  Pharm Res       Date:  2012-10-02       Impact factor: 4.200

3.  Ex vivo investigation of ocular tissue distribution following intravitreal administration of connexin43 mimetic peptide using the microdialysis technique and LC-MS/MS.

Authors:  Rohit Bisht; Abhirup Mandal; Ilva D Rupenthal; Ashim K Mitra
Journal:  Drug Deliv Transl Res       Date:  2016-12       Impact factor: 4.617

4.  Vitreal pharmacokinetics of peptide-transporter-targeted prodrugs of ganciclovir in conscious animals.

Authors:  Kumar G Janoria; Sai H S Boddu; Subramanian Natesan; Ashim K Mitra
Journal:  J Ocul Pharmacol Ther       Date:  2010-06       Impact factor: 2.671

5.  Preclinical assessment of nanostructured liquid crystalline particles for the management of bacterial keratitis: in vivo and pharmacokinetics study.

Authors:  Shreya Kaul; Upendra Nagaich; Navneet Verma
Journal:  Drug Deliv Transl Res       Date:  2021-09-28       Impact factor: 4.617

6.  Prediction of vitreal half-life based on drug physicochemical properties: quantitative structure-pharmacokinetic relationships (QSPKR).

Authors:  Chandrasekar Durairaj; Jaymin C Shah; Shruti Senapati; Uday B Kompella
Journal:  Pharm Res       Date:  2008-10-08       Impact factor: 4.200

7.  AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives.

Authors:  Chandra S Chaurasia; Markus Müller; Edward D Bashaw; Eva Benfeldt; Jan Bolinder; Ross Bullock; Peter M Bungay; Elizabeth C M DeLange; Hartmut Derendorf; William F Elmquist; Margareta Hammarlund-Udenaes; Christian Joukhadar; Dean L Kellogg; Craig E Lunte; Carl Henrik Nordstrom; Hans Rollema; Ronald J Sawchuk; Belinda W Y Cheung; Vinod P Shah; Lars Stahle; Urban Ungerstedt; Devin F Welty; Helen Yeo
Journal:  Pharm Res       Date:  2007-03-27       Impact factor: 4.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.